+

US20020081338A1 - Composition for treating dry eye - Google Patents

Composition for treating dry eye Download PDF

Info

Publication number
US20020081338A1
US20020081338A1 US09/892,040 US89204001A US2002081338A1 US 20020081338 A1 US20020081338 A1 US 20020081338A1 US 89204001 A US89204001 A US 89204001A US 2002081338 A1 US2002081338 A1 US 2002081338A1
Authority
US
United States
Prior art keywords
calcium
eye
ophthalmic composition
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/892,040
Inventor
Donald MacKeen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/926,244 external-priority patent/US5290572A/en
Priority claimed from US07/986,932 external-priority patent/US5366739A/en
Application filed by Individual filed Critical Individual
Priority to US09/892,040 priority Critical patent/US20020081338A1/en
Publication of US20020081338A1 publication Critical patent/US20020081338A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • Dry eye also known as keratoconjunctivitis sicca
  • keratoconjunctivitis sicca is a common ophthalmological disorder affecting millions of Americans. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. It is one of the most common of human eye diseases and is generally treated through the topical delivery of a variety of therapeutic agents.
  • Dry eye may afflict an individual in varying severity.
  • a patient may experience burning, a feeling of dryness, and persistent irritation when debris lodge between the eye lid and the eye surface.
  • vision can be substantially impaired.
  • Eye care practitioners have taken several approaches to the treatment of dry eye.
  • One common approach has been to supplement and stabilize the preocular tear film using artificial tears.
  • Another approach has been the use of ocular inserts that function to provide a tear substitute or to stimulate endogenous tears.
  • Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, and aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids. Another recent approach involves the provision of lubricating substances in lieu of artificial tears. Other treatments involve the use of hormones, such a conjugated estrogens, to treat dry eye in post-menopausal women.
  • ocular inserts are often difficult to insert and uncomfortable when used as intended. Further, as foreign bodies, ocular inserts pose a risk of acting as a vector for infectious organisms.
  • the treatment should be capable of treating dry eye due to a variety of causes. Further, the treatment should not require the application of a drug on a very frequent basis, and should be easy to use. Also, the treatment should not cause discomfort itself and should cause minimal blurring, if any.
  • a calcium-based ophthalmic composition for treatment of dry eye syndrome.
  • the calcium-based ophthalmic composition includes an ophthalmologically acceptable hydrophobic carrier and an ophthalmologically acceptable calcium salt dispersed in the carrier.
  • the hydrophobic carrier is preferably petrolatum or a combination of petrolatum and white wax.
  • the calcium salt is preferably selected from the group consisting of calcium carbonate, calcium sulfate, calcium tartrate, calcium magnesium carbonate, calcium metasilicate, calcium malate, secondary calcium orthophosphate, or a combination of the preceding.
  • a method of treating a patient with dry eye comprising the step of administering a calcium-based ophthalmic composition according to present invention to the patient's eye, eye lid or to the skin surrounding the patient's eye.
  • the composition is administered to the lateral portion of the lower eyelid.
  • FIG. 1 is a table listing the signs and symptoms observed at the initial examination of patients who underwent a clinical trial of the calcium-based pharmaceutical composition according to one embodiment of the present invention
  • FIGS. 2 to 4 are graphs demonstrating the changes in corneal thickness, TBUT, and height of the lower meniscus, respectively, in 15 of the 60 patients following the first application of the calcium-based pharmaceutical composition during the clinical trial;
  • FIG. 5 is a table listing the improvements in signs and symptoms observed during daily treatment with the calcium-based pharmaceutical composition during the clinical trial.
  • FIG. 6 is a table listing the outcome of the patients whose therapies were monitored during the clinical trial.
  • a method of delivering a pharmaceutical composition to the eye includes the step of placing the pharmaceutical composition on the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin. Placement of the pharmaceutical agent is accomplished manually or by a suitable applicator, such as a cotton swab. Movements of the extra-ocular muscles involved in the blink response transport a portion of the composition into the interpalpebral space. The drug is then released by dissolution into the tear film to treat diseases and conditions of the cornea and adnexa. Drugs with the chemical capacity to pass through corneal tissue can also enter the eye to treat diseases and conditions within the eye.
  • Dosages of pharmaceutical compositions delivered by this method do not depend directly on the amount of the composition placed on the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin because only a small portion of the composition is delivered during each blink. Dosing of the pharmaceutical composition can, therefore, be regulated by varying the time between applications.
  • the type of drug to be delivered according to the method disclosed herein as part of the pharmaceutical composition will depend primarily on the disease or condition to be treated.
  • examples of drugs that can be used with the method include drugs used to treat dry eye such as cyclosporine A, vitamin A alcohol, and testosterone; drugs used to treat glaucoma such as pilocarpine, beta blockers, and carbonic anhydrase inhibitors; and drugs used to treat keratopathies such as antifungals and antivirals.
  • Other suitable drugs can be used as will be understood by those with skill in the art with reference to the disclosure herein.
  • compositions to be delivered by this method are prepared by mixing a suitable drug with a pharmacologically acceptable carrier.
  • the appropriateness of the carrier is determined by its pharmacological acceptability for introduction onto or within the eye, and by the chemical characteristics of the drug that is to be admixed with the carrier.
  • the carrier can be a wide variety of compounds such as water-based solutions and gels, the preferred carrier is hydrophobic and will not readily evaporate in air.
  • Carriers such as ophthalmological grade petrolatum and other water-free compounds are preferred because their use decreases or eliminates the need for preservatives.
  • Petrolatum is particularly preferred as a carrier because it is hydrophobic, can be obtained in a suitable pure state, will not evaporate, and is an excellent solvent for lipids. Further, it is inert and noninteractive with ocular tissues.
  • Appropriate amounts of drug and carrier for preparation of the pharmaceutical composition can be determined by those with skill in the art with reference to the disclosure herein. Delivery of the drug can be extended over time by utilizing a chemical form of the drug that is at least partly insoluble in water. The greater the insolubility, the longer the drug will take to dissolve and, thus, come into contact with eye tissue.
  • an ophthalmic pharmaceutical composition for topical administration.
  • the composition comprises a minimally water-soluble, calcium-based composition.
  • the composition can be administered by application directly to the cornea or conjunctiva or can be administered in conjunction with ocular inserts or can be administered by placing the composition on the skin adjacent the eyelids, such as adjacent the lateral eyelid margins, or by placing the composition on the lateral portion of the lower eyelid margin.
  • the calcium salt is preferably largely insoluble in water to facilitate a slow release of calcium ion into the tear film. This decreases the need for continuous or frequent application of the composition.
  • Suitable calcium salts include calcium carbonate (CaCO 3 ), calcium sulfate (CaSO 4 ), calcium tartrate (CaC 4 H 4 O 6 ), calcium magnesium carbonate (CaCO 3 MgCO 3 ), calcium metasilicate (CaSiO 3 ), calcium malate (Ca 4 H 4 O 6 ), secondary calcium orthophosphate (CaHPO 4 ), and similar poorly water soluble calcium salts that are physiologically compatible and stable.
  • calcium carbonate with a solubility of 0.0014 gm/100 ml in cold water, is preferred.
  • the calcium salt is finely divided, preferably into microfine particles having a mean diameter of about 60 microns or less. In another preferred embodiment, the mean particle diameter is between about 10 to 60 microns.
  • the calcium-based pharmaceutical composition further includes a hydrophobic carrier.
  • the hydrophobic carrier tends to supply calcium ion to the cornea and conjunctiva for a longer period than a typical hydrophilic carrier.
  • a composition having a hydrophobic carrier according to the present invention can be applied to the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin according to the methods disclosed herein.
  • the preferred carrier for a drug for treating dry eye is hydrophobic and sufficiently viscous to prevent dripping or running after application to the skin adjacent the eyelids. Further, using a hydrophobic, water-free carrier advantageously reduces or eliminates the need for a preservative.
  • the carrier is petrolatum. The melting point of petrolatum can be increased by the admixture of a suitable substance such as white wax.
  • the pharmaceutical composition is prepared by mixing a poorly water-soluble calcium salt and a pharmacologically acceptable carrier.
  • the calcium salt can be divided into microfine particles by any standard means, such as pulverization in a mortar and pestle.
  • the composition is prepared by levigation with a polyol such as glycerol or propylene glycol.
  • levigation is performed with glycerol and light calcium carbonate in about a two to one ratio by weight.
  • a pharmaceutical composition according to the present invention can be prepared with final ratios by weight of light calcium carbonate/glycerol/petrolatum of approximately 1/2/7.
  • the composition includes an agent to enhance the interface between the hydrophilic polyol milieu surrounding the calcium salt and the hydrophobic carrier.
  • an agent to enhance the interface between the hydrophilic polyol milieu surrounding the calcium salt and the hydrophobic carrier advantageously promotes stability and enhances transfer of the pharmaceutical composition while heated into containers.
  • the agent can be selected from the group consisting of polyethylene glycol, glyceryl cocolate, sulfosuccinates, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80, or can be other suitable agents as will be understood by those with skill in the art with reference to the disclosure herein.
  • the agent is anhydrous lanolin.
  • the agent is present in an amount less than about 0.5 percent by weight.
  • the pharmaceutical composition includes petrolatum as a carrier
  • sterilization is preferably accomplished by heating at about 120° C. for about 20 minutes in a suitable sterile container. Further, the composition is processed and stored in a manner which avoids exposing the petrolatum to ultraviolet radiation to avoid accelerating breakdown of the carrier.
  • a calcium-based pharmaceutical composition can be applied topically to the eye, either directly to the cornea or conjunctiva, indirectly by application to the skin adjacent to the eyelids or to the lateral portion of the lower eyelid margin, or through the use of an ocular insert or similar device. Although any of these methods of application are suitable, in a preferred embodiment the composition is applied to the lateral portion of the lower eyelid margin according to the method disclosed herein.
  • the pharmaceutical composition used to treat these patients contained calcium carbonate which was finely dispersed in a water-free vehicle consisting primarily of petrolatum according to the present invention.
  • the composition was free of preservatives.
  • the pharmaceutical composition was administered by application to the skin of the lateral canthal area or streaked along the lateral portion of the lower eyelid margin.
  • the patients were treated for between 1 and 12 weeks, with an average duration of treatment of between 14 and 21 days.
  • each patient had central corneal thickness, tear break-up time and the height of the central lower meniscus measured.
  • FIGS. 2 to 4 the graphs shown demonstrate the changes in corneal thickness, TBUT, and height of the lower meniscus, respectively, in 15 of the 60 patients following the first application of calcium-based pharmaceutical composition. All of these measurements show statistically significant improvements.
  • the average corneal thickness was 8 ⁇ greater than the average normal (0 value on the ordinate) for this population of Europeans, 545 ⁇ M ⁇ 20 ⁇ . Each error bar equals ⁇ 1 SD.
  • the ordinate of the graph indicates corneal swelling or deswelling by positive and negative values respectively.
  • the average corneal thickness value decreased below 0. The deswelling continued in time, and reached a maximum of approximately 5 ⁇ M less than normal in an interval of 5 to 12 hours.
  • the initial average tear break-up time was 2 seconds.
  • the value increased rapidly to a maximum of 17 seconds in an 8 to 12 hour interval. By 20 hours, the value was still significantly greater than the starting value.
  • the average value could be considered as normal by most criteria.
  • meniscus height increased rapidly and reached a maximal value during an interval of 6 to 10 hours. At 20 hours the meniscus heights were still significantly greater than the starting value.
  • FIG. 5 there is shown a table listing the improvements in signs and symptoms observed during daily treatment.
  • the improvement in signs included a decrease in conjunctival injection and chemosis, a decrease in lid swelling, a decrease in rose bengal staining, and an increase in TBUT.
  • the improvement in symptoms included a decrease in burning, itching, and a feeling of grittiness.
  • FIG. 6 there is shown a table listing the outcome of the patients whose therapeutic outcomes were a success, a partial success, or failure. As can be seen, ninety-seven percent of the patients obtained total or partial improvement. Sixty-seven percent of the patients experienced complete elimination of all signs and symptoms. Thirty percent of the patients experienced significant clinical improvement and obtained subjective relief.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present Application claims the benefit of United States Provisional Patent Application No. 60/215,734, filed Jun. 28, 2000; and the present application is a continuation of U.S. patent application Ser. No. 09/177,903, filed Oct. 23, 1998, now U.S. Pat. No. 6,254,893; which is a Divisional of U.S. patent application Ser. No. 08/785,080, filed Jan. 21, 1997, now U.S. Pat. No. 5,830,508; which is a continuation-in-part of U.S. patent application Ser. No. 08/144,643, filed Oct. 28, 1993, now U.S. Pat. No. 5,595,764; which is a continuation of U.S. patent application Ser. No. 07/986,932, filed Dec. 8, 1992, now U.S. Pat. No. 5,366,739; which is a continuation in U.S. patent application Ser. No. 07/926,244, filed Aug. 6, 1992, now U.S. Pat. No. 5,290,572; the contents of which are each incorporated herein by reference in their entirety.[0001]
    • BACKGROUND
  • Dry eye, also known as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. It is one of the most common of human eye diseases and is generally treated through the topical delivery of a variety of therapeutic agents. [0002]
  • Dry eye may afflict an individual in varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation when debris lodge between the eye lid and the eye surface. In severe cases, vision can be substantially impaired. [0003]
  • Although it appears that dry eye can result from a number of unrelated pathogenic causes, all presentations of the syndrome have in common the breakdown of the pre-ocular tear film. This breakdown results in dehydration of the exposed cornea and conjunctiva and many of symptoms associated with dry eye. [0004]
  • Eye care practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the preocular tear film using artificial tears. Another approach has been the use of ocular inserts that function to provide a tear substitute or to stimulate endogenous tears. [0005]
  • Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, and aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids. Another recent approach involves the provision of lubricating substances in lieu of artificial tears. Other treatments involve the use of hormones, such a conjugated estrogens, to treat dry eye in post-menopausal women. [0006]
  • Although these approaches have met with some success, there remains problems in the treatment of dry eye. The use of tear substitutes, for example, generally requires many repeated applications over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such dosing is cumbersome and time consuming, increases the exposure of the eye to preservative agents present in many artificial tears. [0007]
  • Similarly, ocular inserts are often difficult to insert and uncomfortable when used as intended. Further, as foreign bodies, ocular inserts pose a risk of acting as a vector for infectious organisms. [0008]
  • Therefore, there remains a need for a safe and effective treatment for dry eye. Ideally, the treatment should be capable of treating dry eye due to a variety of causes. Further, the treatment should not require the application of a drug on a very frequent basis, and should be easy to use. Also, the treatment should not cause discomfort itself and should cause minimal blurring, if any. [0009]
    • SUMMARY
  • According to one embodiment of the present invention, there is provided a calcium-based ophthalmic composition for treatment of dry eye syndrome. The calcium-based ophthalmic composition includes an ophthalmologically acceptable hydrophobic carrier and an ophthalmologically acceptable calcium salt dispersed in the carrier. The hydrophobic carrier is preferably petrolatum or a combination of petrolatum and white wax. The calcium salt is preferably selected from the group consisting of calcium carbonate, calcium sulfate, calcium tartrate, calcium magnesium carbonate, calcium metasilicate, calcium malate, secondary calcium orthophosphate, or a combination of the preceding. [0010]
  • According to another embodiment of the present invention, there is provided a method of treating a patient with dry eye comprising the step of administering a calcium-based ophthalmic composition according to present invention to the patient's eye, eye lid or to the skin surrounding the patient's eye. In a preferred embodiment, the composition is administered to the lateral portion of the lower eyelid.[0011]
    • FIGURES
  • These and other features, aspects and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying figures where: [0012]
  • FIG. 1 is a table listing the signs and symptoms observed at the initial examination of patients who underwent a clinical trial of the calcium-based pharmaceutical composition according to one embodiment of the present invention; [0013]
  • FIGS. [0014] 2 to 4 are graphs demonstrating the changes in corneal thickness, TBUT, and height of the lower meniscus, respectively, in 15 of the 60 patients following the first application of the calcium-based pharmaceutical composition during the clinical trial;
  • FIG. 5 is a table listing the improvements in signs and symptoms observed during daily treatment with the calcium-based pharmaceutical composition during the clinical trial; and [0015]
  • FIG. 6 is a table listing the outcome of the patients whose therapies were monitored during the clinical trial. [0016]
    • DESCRIPTION
  • According to one aspect of the present invention, there is provided a method of delivering a pharmaceutical composition to the eye. The method includes the step of placing the pharmaceutical composition on the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin. Placement of the pharmaceutical agent is accomplished manually or by a suitable applicator, such as a cotton swab. Movements of the extra-ocular muscles involved in the blink response transport a portion of the composition into the interpalpebral space. The drug is then released by dissolution into the tear film to treat diseases and conditions of the cornea and adnexa. Drugs with the chemical capacity to pass through corneal tissue can also enter the eye to treat diseases and conditions within the eye. [0017]
  • Dosages of pharmaceutical compositions delivered by this method do not depend directly on the amount of the composition placed on the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin because only a small portion of the composition is delivered during each blink. Dosing of the pharmaceutical composition can, therefore, be regulated by varying the time between applications. [0018]
  • The type of drug to be delivered according to the method disclosed herein as part of the pharmaceutical composition will depend primarily on the disease or condition to be treated. Examples of drugs that can be used with the method include drugs used to treat dry eye such as cyclosporine A, vitamin A alcohol, and testosterone; drugs used to treat glaucoma such as pilocarpine, beta blockers, and carbonic anhydrase inhibitors; and drugs used to treat keratopathies such as antifungals and antivirals. Other suitable drugs can be used as will be understood by those with skill in the art with reference to the disclosure herein. [0019]
  • Pharmaceutical compositions to be delivered by this method are prepared by mixing a suitable drug with a pharmacologically acceptable carrier. The appropriateness of the carrier is determined by its pharmacological acceptability for introduction onto or within the eye, and by the chemical characteristics of the drug that is to be admixed with the carrier. [0020]
  • Although the carrier can be a wide variety of compounds such as water-based solutions and gels, the preferred carrier is hydrophobic and will not readily evaporate in air. Carriers such as ophthalmological grade petrolatum and other water-free compounds are preferred because their use decreases or eliminates the need for preservatives. Petrolatum is particularly preferred as a carrier because it is hydrophobic, can be obtained in a suitable pure state, will not evaporate, and is an excellent solvent for lipids. Further, it is inert and noninteractive with ocular tissues. [0021]
  • Appropriate amounts of drug and carrier for preparation of the pharmaceutical composition can be determined by those with skill in the art with reference to the disclosure herein. Delivery of the drug can be extended over time by utilizing a chemical form of the drug that is at least partly insoluble in water. The greater the insolubility, the longer the drug will take to dissolve and, thus, come into contact with eye tissue. [0022]
  • According to another aspect of the present invention, there is provided an ophthalmic pharmaceutical composition for topical administration. The composition comprises a minimally water-soluble, calcium-based composition. The composition can be administered by application directly to the cornea or conjunctiva or can be administered in conjunction with ocular inserts or can be administered by placing the composition on the skin adjacent the eyelids, such as adjacent the lateral eyelid margins, or by placing the composition on the lateral portion of the lower eyelid margin. [0023]
  • The calcium salt is preferably largely insoluble in water to facilitate a slow release of calcium ion into the tear film. This decreases the need for continuous or frequent application of the composition. Suitable calcium salts include calcium carbonate (CaCO[0024] 3), calcium sulfate (CaSO4), calcium tartrate (CaC4H4O6), calcium magnesium carbonate (CaCO3 MgCO3), calcium metasilicate (CaSiO3), calcium malate (Ca4H4O6), secondary calcium orthophosphate (CaHPO4), and similar poorly water soluble calcium salts that are physiologically compatible and stable. Among these calcium salts, calcium carbonate, with a solubility of 0.0014 gm/100 ml in cold water, is preferred.
  • In a preferred embodiment, the calcium salt is finely divided, preferably into microfine particles having a mean diameter of about 60 microns or less. In another preferred embodiment, the mean particle diameter is between about 10 to 60 microns. [0025]
  • The calcium-based pharmaceutical composition further includes a hydrophobic carrier. The hydrophobic carrier tends to supply calcium ion to the cornea and conjunctiva for a longer period than a typical hydrophilic carrier. Further, a composition having a hydrophobic carrier according to the present invention can be applied to the skin adjacent to the lateral canthus or on the lateral portion of the lower eyelid margin according to the methods disclosed herein. [0026]
  • The preferred carrier for a drug for treating dry eye is hydrophobic and sufficiently viscous to prevent dripping or running after application to the skin adjacent the eyelids. Further, using a hydrophobic, water-free carrier advantageously reduces or eliminates the need for a preservative. In a preferred embodiment, the carrier is petrolatum. The melting point of petrolatum can be increased by the admixture of a suitable substance such as white wax. [0027]
  • The pharmaceutical composition is prepared by mixing a poorly water-soluble calcium salt and a pharmacologically acceptable carrier. The calcium salt can be divided into microfine particles by any standard means, such as pulverization in a mortar and pestle. In a preferred embodiment, the composition is prepared by levigation with a polyol such as glycerol or propylene glycol. In a particularly preferred embodiment, levigation is performed with glycerol and light calcium carbonate in about a two to one ratio by weight. When prepared in this manner, a pharmaceutical composition according to the present invention can be prepared with final ratios by weight of light calcium carbonate/glycerol/petrolatum of approximately 1/2/7. [0028]
  • In another preferred embodiment, the composition includes an agent to enhance the interface between the hydrophilic polyol milieu surrounding the calcium salt and the hydrophobic carrier. Inclusion of the agent advantageously promotes stability and enhances transfer of the pharmaceutical composition while heated into containers. The agent can be selected from the group consisting of polyethylene glycol, glyceryl cocolate, sulfosuccinates, [0029] polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80, or can be other suitable agents as will be understood by those with skill in the art with reference to the disclosure herein. In a preferred embodiment, the agent is anhydrous lanolin. In a particularly preferred embodiment, the agent is present in an amount less than about 0.5 percent by weight.
  • It will be apparent that the use of calcium ion to treat dry eye does not exclude the use of other known therapies. It is, therefore, within the scope of this invention to combine the delivery of calcium ion as disclosed herein with other drugs, such as retinoids, or estrogens. However, it is preferable to avoid combining the calcium-based composition of the present invention with drugs that include chelating or other binding agents having an affinity for ionic calcium as these combinations would decrease the efficacy of the calcium-based pharmaceutical composition disclosed herein. [0030]
  • When the pharmaceutical composition includes petrolatum as a carrier, sterilization is preferably accomplished by heating at about 120° C. for about 20 minutes in a suitable sterile container. Further, the composition is processed and stored in a manner which avoids exposing the petrolatum to ultraviolet radiation to avoid accelerating breakdown of the carrier. [0031]
  • A calcium-based pharmaceutical composition, according to the present invention, can be applied topically to the eye, either directly to the cornea or conjunctiva, indirectly by application to the skin adjacent to the eyelids or to the lateral portion of the lower eyelid margin, or through the use of an ocular insert or similar device. Although any of these methods of application are suitable, in a preferred embodiment the composition is applied to the lateral portion of the lower eyelid margin according to the method disclosed herein. [0032]
    • EXAMPLE Clinical Trial Utilizing the Composition and Method According to the Present Invention
  • A clinical trial was performed to determine the effects of a calcium-based pharmaceutical composition according to the present invention and the results were published in MacKeen, Donald L., Roth, Hans-Walter, [0033] A Preliminary Report on a New Method for the Treatment of Dry Eye, Practical Optometry 6:3, 1995, incorporated herein by reference in its entirety. In summary, the study group involved 60 patients with dry eye (22 males, 38 females), ranging in age from 20 to 88 years. The patients were unresponsive to conventional dry eye/blepharitis treatments. All 60 patients had chronic conjunctivitis and 58 had blepharitis. Referring now to FIG. 1, there is shown a table listing the signs and symptoms observed at the initial examination.
  • The pharmaceutical composition used to treat these patients contained calcium carbonate which was finely dispersed in a water-free vehicle consisting primarily of petrolatum according to the present invention. The composition was free of preservatives. [0034]
  • The pharmaceutical composition was administered by application to the skin of the lateral canthal area or streaked along the lateral portion of the lower eyelid margin. The patients were treated for between 1 and 12 weeks, with an average duration of treatment of between 14 and 21 days. [0035]
  • During the first 20 hours following initial administration of the pharmaceutical composition, each patient had central corneal thickness, tear break-up time and the height of the central lower meniscus measured. Follow-up tests included slit-lamp examination, expression of lower lid meibomian glands, assessment of subjective response, tear break-up time, Schirmer test I, rose bengal staining, and fluorescein staining. [0036]
  • The results of this study were as follows. Many patients reported an improvement in visual acuity shortly after application of the calcium-based pharmaceutical composition and symptomatic improvement in the first day of treatment. No patient reported blurring from the treatment. [0037]
  • Referring now to FIGS. [0038] 2 to 4, the graphs shown demonstrate the changes in corneal thickness, TBUT, and height of the lower meniscus, respectively, in 15 of the 60 patients following the first application of calcium-based pharmaceutical composition. All of these measurements show statistically significant improvements.
  • As can be seen in FIG. 2, the average corneal thickness was 8μ greater than the average normal (0 value on the ordinate) for this population of Europeans, 545 μM±20μ. Each error bar equals ±1 SD. The ordinate of the graph indicates corneal swelling or deswelling by positive and negative values respectively. Four hours following a single administration of the composition, the average corneal thickness value decreased below 0. The deswelling continued in time, and reached a maximum of approximately 5 μM less than normal in an interval of 5 to 12 hours. [0039]
  • As can be seen in FIG. 3, the initial average tear break-up time (TBUT) was 2 seconds. The value increased rapidly to a maximum of 17 seconds in an 8 to 12 hour interval. By 20 hours, the value was still significantly greater than the starting value. The average value could be considered as normal by most criteria. [0040]
  • As can be seen in FIG. 4, meniscus height increased rapidly and reached a maximal value during an interval of 6 to 10 hours. At 20 hours the meniscus heights were still significantly greater than the starting value. [0041]
  • Many patients reported symptomatic improvement in one day. All experienced improvement within seven days of treatment. [0042]
  • Referring now to FIG. 5, there is shown a table listing the improvements in signs and symptoms observed during daily treatment. The improvement in signs included a decrease in conjunctival injection and chemosis, a decrease in lid swelling, a decrease in rose bengal staining, and an increase in TBUT. The improvement in symptoms included a decrease in burning, itching, and a feeling of grittiness. [0043]
  • Referring now to FIG. 6, there is shown a table listing the outcome of the patients whose therapeutic outcomes were a success, a partial success, or failure. As can be seen, ninety-seven percent of the patients obtained total or partial improvement. Sixty-seven percent of the patients experienced complete elimination of all signs and symptoms. Thirty percent of the patients experienced significant clinical improvement and obtained subjective relief. [0044]
  • Subjects with Schirmer values <1 mm per 5 minutes and corneal decompensation and those with severe allergies, e.g. atopy, did not respond to this therapy. However, these subjects reported that this treatment was neither worse nor better than previous treatments. One patient who failed this treatment was found to be sensitive to Vaseline® by skin testing. [0045]
  • During the early part of one study, supplies of the calcium-based pharmaceutical composition were not constant for each patient. As a result many patients went without the ointment, but retained temporary remissions without treatment which ranged from weeks to as long as six months. [0046]
  • Although the present invention has been discussed in considerable detail with reference to certain preferred embodiments, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of preferred embodiments contained herein. [0047]

Claims (12)

I claim:
1. A calcium-based ophthalmic composition for treatment of dry eye syndrome comprising:
a) an ophthalmologically acceptable hydrophobic carrier; and
b) dispersed within the carrier, an ophthalmologically acceptable calcium salt.
2. The ophthalmic composition of claim 1, wherein the hydrophobic carrier is selected from the group consisting of petrolatum and a combination of petrolatum and white wax.
3. The ophthalmic composition of claim 1, wherein the calcium salt is selected from the group consisting of calcium carbonate, calcium sulfate, calcium tartrate, calcium magnesium carbonate, calcium metasilicate, calcium malate, secondary calcium orthophosphate, combinations of the preceding and at least one of the preceding in combination with calcium carbonate or calcium sulfate.
4. The ophthalmic composition of claim 1, where the calcium salt has particles having a mean diameter of less than about 60 microns.
5. The ophthalmic composition of claim 1, where the calcium salt is present in an amount of between about 2% and 25% by weight.
6. A calcium-based ophthalmic composition for treatment of dry eye syndrome consisting essentially of:
a) an ophthalmologically acceptable hydrophobic carrier; and
b) dispersed within the carrier, an ophthalmologically acceptable calcium salt.
7. The ophthalmic composition of claim 6, wherein the hydrophobic carrier is selected from the group consisting of petrolatum and a combination of petrolatum and white wax.
8. The ophthalmic composition of claim 6, wherein the calcium salt is selected from the group consisting of calcium carbonate, calcium sulfate, calcium tartrate, calcium magnesium carbonate, calcium metasilicate, calcium malate, secondary calcium orthophosphate, combinations of the preceding and at least one of the preceding in combination with calcium carbonate or calcium sulfate.
9. The ophthalmic composition of claim 6, where the calcium salt has particles having a mean diameter of less than about 60 microns.
10. The ophthalmic composition of claim 6, where the calcium salt is present in an amount of between about 2% and 25% by weight.
11. A method of treating a patient with dry eye comprising the step of administering a composition according to claim 1 to the patient's eye, eye lid or to the skin surrounding the patient's eye.
12. A method of treating a patient with dry eye comprising the step of administering a composition according to claim 6 to the patient's eye, eye lid or to the skin surrounding the patient's eye.
US09/892,040 1992-08-06 2001-06-26 Composition for treating dry eye Abandoned US20020081338A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/892,040 US20020081338A1 (en) 1992-08-06 2001-06-26 Composition for treating dry eye

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/926,244 US5290572A (en) 1992-08-06 1992-08-06 Opthalmic composition for treating dry eye
US07/986,932 US5366739A (en) 1992-08-06 1992-12-08 Method of ophthalmic drug delivery
US08/144,643 US5595764A (en) 1992-08-06 1993-10-28 Ophthalmic composition for treating dry eye
US08/785,080 US5830508A (en) 1992-08-06 1997-01-21 Composition for treating dry eye
US09/177,903 US6254893B1 (en) 1992-08-06 1998-10-23 Composition for treating dry eye
US21573400P 2000-06-28 2000-06-28
US09/892,040 US20020081338A1 (en) 1992-08-06 2001-06-26 Composition for treating dry eye

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/177,903 Continuation US6254893B1 (en) 1992-08-06 1998-10-23 Composition for treating dry eye

Publications (1)

Publication Number Publication Date
US20020081338A1 true US20020081338A1 (en) 2002-06-27

Family

ID=27386140

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/785,080 Expired - Fee Related US5830508A (en) 1992-08-06 1997-01-21 Composition for treating dry eye
US09/177,903 Expired - Lifetime US6254893B1 (en) 1992-08-06 1998-10-23 Composition for treating dry eye
US09/892,040 Abandoned US20020081338A1 (en) 1992-08-06 2001-06-26 Composition for treating dry eye

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/785,080 Expired - Fee Related US5830508A (en) 1992-08-06 1997-01-21 Composition for treating dry eye
US09/177,903 Expired - Lifetime US6254893B1 (en) 1992-08-06 1998-10-23 Composition for treating dry eye

Country Status (1)

Country Link
US (3) US5830508A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110429A1 (en) * 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
WO2007145618A1 (en) * 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
US20140011750A1 (en) * 2005-10-14 2014-01-09 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
CN101065139A (en) * 2004-10-09 2007-10-31 扶瑞药业股份有限公司 Ocular agent delivery systems
WO2006087968A1 (en) * 2005-02-17 2006-08-24 Senju Pharmaceutical Co, . Ltd. Solid ophthalmic drug for external use
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2197461B1 (en) 2007-10-08 2018-02-21 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
US20090118262A1 (en) * 2007-11-01 2009-05-07 Rohrs Brian R Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery
CA2703000C (en) * 2007-11-05 2013-08-06 Bausch & Lomb Incorporated Water-immiscible materials as vehicles for drug delivery
MX338355B (en) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Topical drug delivery systems for ophthalmic use.
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1070593A (en) * 1962-12-26 1967-06-01 Olin Mathieson Ophthalmic ointment composition and the preparation thereof
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
JPS5936606A (en) * 1982-08-26 1984-02-28 Sogo Yatsukou Kk Cosmetic
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
US4579131A (en) * 1985-06-26 1986-04-01 Syed Ali N Hair softening method and compositions
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4866049A (en) * 1987-08-10 1989-09-12 Spectra Pharmaceutical Services, Inc. Ophthalmic compositionn and method of using same
JPH0667850B2 (en) 1987-09-03 1994-08-31 ユニバーシティ オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ophthalmic cyclosporin composition
US4957918A (en) * 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
FR2638089A1 (en) * 1988-10-26 1990-04-27 Sandoz Sa NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE
US4951683A (en) * 1989-01-19 1990-08-28 Davis Jeffrey P Device for detecting keratoconjunctivitis sicca
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
JP3256997B2 (en) 1990-08-30 2002-02-18 千寿製薬株式会社 Stable aqueous formulation
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110429A1 (en) * 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
US20090214619A1 (en) * 2004-11-24 2009-08-27 Therakine Ltd. Implant for intraocular drug delivery
US20140011750A1 (en) * 2005-10-14 2014-01-09 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US10610565B2 (en) 2005-10-14 2020-04-07 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
WO2007145618A1 (en) * 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
US20100028328A1 (en) * 2006-06-12 2010-02-04 Therakine, Ltd. Topical treatment for diseases of eye surface

Also Published As

Publication number Publication date
US6254893B1 (en) 2001-07-03
US5830508A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
US5290572A (en) Opthalmic composition for treating dry eye
AU677980B2 (en) Method of ophthalmic drug delivery
TWI335819B (en) Use of oculosurface selective glucocorticoid in the treatment of dry eye
US6254893B1 (en) Composition for treating dry eye
Harbour et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema
KR100452715B1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ischemia
US6656460B2 (en) Method and composition for dry eye treatment
US20210008079A1 (en) Treatment for dry eye
Chang et al. Phase II results of an intraocular steroid delivery system for cataract surgery
US6096733A (en) Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CN104661663A (en) Compositions and treatment for eye diseases and disorders
JP2003523925A (en) Ophthalmic solution containing tetracycline for topical treatment of dry eye disease
Berdy et al. Allergic conjunctivitis: a survey of new antihistamines
WO1989002270A1 (en) Method of lowering intraocular (eye) pressure
CRAIG BROWN et al. Use of dilute drug solutions for routine cycloplegia and mydriasis
JP2025513090A (en) Pharmaceutical Compositions of Mycophenolic Acid and/or Betamethasone for the Treatment of Eye Diseases - Patent application
US20120164213A1 (en) Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
JPS63502270A (en) Ophthalmic pharmaceutical composition having mydriatic effect
EP4259125A1 (en) Apremilast ophthalmic compositions
Lewis et al. Aminozolamide suspension: the role of the vehicle in a topical carbonic anhydrase inhibitor
Carruthers et al. innervation and its change with age, which we have
AU2532588A (en) Method of lowering intraocular (eye) pressure
JPH06511014A (en) Ophthalmic solutions, such as verapamil hydrochloride formulations containing a buffer system, for administration to the eye

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载